Demographic and baseline patient characteristics
| Characteristic . | Patients with AA (n = 116) . |
|---|---|
| Mean age ± SD, y | 33.3 ± 17.1 |
| Age group, y | |
| 2 to less than 16, n (%) | 16 (13.8) |
| 16 or older, n (%) | 100 (86.2) |
| Male/female, n | 67:49 |
| Race (White/Black/Asian), n | 32:4:80 |
| Chelation-naive, n (%) | 79 (68.1) |
| Previous iron chelation therapy, n (%) | |
| DFO monotherapy | 31 (26.7) |
| DFO + deferiprone combination | 6 (5.2) |
| Mean duration of previous iron chelation therapy ± SD, y | 4.3 ± 5.8 |
| Mean duration of transfusion history ± SD, y | 6.1 ± 5.7 |
| Mean no. of transfusion sessions in the year before study entry ± SD | 12.5 ± 13.0 (n = 114) |
| Mean total volume red blood cells transfused in the year before study entry ± SD, mL/kg | 116 ± 179 (n = 112) |
| Median baseline serum ferritin (range), ng/mL | 3254 (908-25 346) (n = 115) |
| Characteristic . | Patients with AA (n = 116) . |
|---|---|
| Mean age ± SD, y | 33.3 ± 17.1 |
| Age group, y | |
| 2 to less than 16, n (%) | 16 (13.8) |
| 16 or older, n (%) | 100 (86.2) |
| Male/female, n | 67:49 |
| Race (White/Black/Asian), n | 32:4:80 |
| Chelation-naive, n (%) | 79 (68.1) |
| Previous iron chelation therapy, n (%) | |
| DFO monotherapy | 31 (26.7) |
| DFO + deferiprone combination | 6 (5.2) |
| Mean duration of previous iron chelation therapy ± SD, y | 4.3 ± 5.8 |
| Mean duration of transfusion history ± SD, y | 6.1 ± 5.7 |
| Mean no. of transfusion sessions in the year before study entry ± SD | 12.5 ± 13.0 (n = 114) |
| Mean total volume red blood cells transfused in the year before study entry ± SD, mL/kg | 116 ± 179 (n = 112) |
| Median baseline serum ferritin (range), ng/mL | 3254 (908-25 346) (n = 115) |